EQS-News: Mainz Biomed Expands Commercial Footprint into Poland
BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.
- BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.
- “Entering the Polish market is an important milestone for the Company and we are thrilled by the opportunity to partner with TESTDNA to establish ColoAlert’s commerical footprint in this territory,” commented Darin Leigh, Chief Commercial Officer of Mainz Biomed.
- Mainz Biomed is providing ColoAlert to TESTDNA under the standard terms of the Company’s partnership agreements.
- In the coming weeks, Mainz Biomed will work with TESTDNA to prepare and launch co-marketing activities to ensure successful commercialization in the Polish market.